Cimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria
Customize your policy alerts
Sign up for Moda Health Policy M-0028 alerts
Get alerted when Policy M-0028 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Defines Moda Health prior authorization, dosing limits, length of authorization, and medical necessity criteria for Cimzia (certolizumab pegol) for multiple indications (e.g., RA, Crohn's disease, PsA, AS, pJIA). Applies to providers requesting coverage for members under Moda Health plans.
Policy Summary
PayerModa Health
PolicyCimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria
Policy CodePolicy M-0028
Change TypeNo material changes
Effective DateMar 3, 2026
Last ReviewMar 3, 2026
Next Review DateMar 3, 2026
Key ActionObtain prior authorization with documentation of baseline objective disease severity, required prior therapy trials or contraindications, and required pre-treatment screening (HBV and latent TB) before initiating Cimzia.
No material clinical or coverage changes in this revision.
180dinitial prior authorization duration
365drenewal prior authorization duration
400common per-dose max
≥2y
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
pJIA min age
200mgcommon maintenance dose
Coverage Criteria and Clinical Requirements
Universal Criteria
Covered when ALL of the following universal criteria are met:
Universal prerequisites: Site-of-care specialty infusion program requirements are met; member is at least 18 years of age unless specified for the indication; HBV screening completed prior to initiating treatment; provider confirms member is up to date with age-appropriate vaccinations prior to initiating therapy.
From Initial Approval / Prior authorization validity
Infection and vaccine screening: Latent tuberculosis (TB) screening completed prior to initiating treatment with ongoing monitoring during therapy; no active infection present; member has not received live vaccines immediately prior to treatment and will not receive live vaccines during therapy.
Universal Criteria
Concomitant therapy: Member is not on concurrent treatment with another biologic therapy or targeted synthetic therapy.
Universal Criteria
Rheumatoid Arthritis (RA)
Covered when ALL of the following are met:
RA baseline assessment: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active rheumatoid arthritis.
RA requirements
Prior therapy requirement: Either: member has had at least a 3-month trial and failed ONE conventional synthetic DMARD (e.g., methotrexate, azathioprine, sulfasalazine, leflunomide, etc.); OR member is already established on biologic or targeted synthetic therapy for RA.3 months
RA clinical trials
Concomitant methotrexate: Prescribed in combination with methotrexate unless the member has a contraindication or intolerance to methotrexate.
RA prescribing
Crohn's Disease (CD)
Covered when ALL of the following are met:
CD baseline assessment: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active Crohn's disease.
CD requirements
Prior therapy requirement: Either: documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum 3-month trial of corticosteroids or immunomodulators (e.g., azathioprine, 6-mercaptopurine, or methotrexate); OR evidence of high-risk disease for which corticosteroids or immunomodulators are inadequate and biologic therapy is necessary; OR member is already established on biologic or targeted synthetic therapy for CD.3 months
CD clinical
Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, ustekinumab SC, guselkumab, upadacitinib, risankizumab, or vedolizumab; OR member is continuing treatment.3 months
Psoriatic Arthritis (PsA)
Covered when ALL of the following are met:
PsA baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active psoriatic arthritis.
PsA requirements
Prior therapy by phenotype: For axial disease or enthesitis: failure of at least a 4-week trial of ONE NSAID unless contraindicated; OR For peripheral arthritis or dactylitis: failure of at least a 3-month trial of ONE csDMARD; OR member is already established on biologic or targeted synthetic therapy for PsA.4 weeks (NSAID) or 3 months (csDMARD)
PsA clinical
Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, ustekinumab, guselkumab, tofacitinib, upadacitinib, risankizumab, or apremilast; OR member is continuing treatment.3 months
Ankylosing Spondylitis (AS)
Covered when ALL of the following are met:
AS baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented active ankylosing spondylitis.
AS requirements
NSAID trial requirement: Either: member had an adequate trial and failure of at least TWO NSAIDs over 4 weeks in total, unless contraindicated; OR member is already established on biologic or targeted synthetic therapy for AS.2 NSAID trials over 4 weeks
AS clinical
Commercial step: Commercial: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, upadacitinib, or tofacitinib; OR member is continuing treatment.3 months
Age requirement: Member is at least 2 years of age.age >= 2 years
pJIA age
pJIA baseline: Physician has assessed baseline disease severity using an objective measure/tool and documented moderate to severe active polyarticular juvenile idiopathic arthritis.
pJIA requirements
Prior therapy requirement: Either: member has had at least a 1-month trial and failure (unless contraindicated or intolerant) of prior therapy with either oral NSAIDs OR csDMARDs (e.g., methotrexate, leflunomide, sulfasalazine); OR member is already established on biologic or targeted synthetic therapy for pJIA.1 month
pJIA prior therapy
General Commercial/Medicaid prior trial requirement (select indications)
Covered when ALL of the following are met for specified member types
trial_requirement: Member has tried and had inadequate response, contraindication, or intolerance to at least a 3-month trial of a specified alternative agent (lists differ for Commercial vs Medicaid) OR member is continuing treatment.3 months
age_and_assessment: Member is at least 2 years of age AND physician has assessed baseline disease severity using an objective measure/tool AND documented moderate to severe active polyarticular disease.age >= 2 years
prior_therapy_or_established: EITHER member had at least a 1-month trial and failure (unless contraindicated or intolerant) of previous therapy with either oral NSAIDs OR csDMARDs (e.g., methotrexate, leflunomide, sulfasalazine) OR member is already established on biologic or targeted synthetic therapy for pJIA.1 month for NSAID/csDMARD trial
objective_inflammation_and_imaging: Physician has assessed baseline disease severity with an objective tool AND objective signs of inflammation (e.g., elevated CRP above the upper limit of normal and/or sacroiliitis on MRI) AND no definitive radiographic structural damage on sacroiliac joints.CRP above ULN or MRI sacroiliitis
prior_nsaid_or_established: EITHER member had an adequate trial and failure of at least TWO NSAIDs unless contraindicated OR member is already established on biologic or targeted synthetic therapy for nr-axSpA.2 NSAID trials
Plaque Psoriasis (PsO) — Initial Therapy
Covered when ALL of the following are met
disease_severity: Physician has assessed baseline disease severity AND documented moderate to severe plaque psoriasis for at least 6 months with at least one of: BSA ≥10% OR PASI ≥10 OR incapacitating/serious emotional consequences or intractable pruritis.>=6 months disease duration
prior_therapies: Member did not respond adequately (or is not a candidate) to: a 4-week minimum trial of topical agents; AND a 3-month minimum trial of at least ONE non-biologic systemic agent; AND a 3-month minimum trial of phototherapy (PUVA or UVB); unless member is already established on biologic/targeted therapy or has >10% BSA involvement.topicals 4 weeks; systemic 3 months; phototherapy 3 months
Note: members ≤90 kg should initiate lower maintenance dosing regimen.
Immune Checkpoint Inhibitor-Related Toxicities
Compendia-recommended use covered when ALL of the following are met
ici_inflammatory_arthritis: Member has been receiving immune checkpoint inhibitor therapy AND has moderate or severe immunotherapy-related inflammatory arthritis AND is unable to taper corticosteroids after one week.unable to taper after 1 week
Compendia recommended indication
Renewal / Response Criteria (by indication)
Authorization renewal requires documented disease response compared to baseline using indication-specific objective measures
RA_response: Rheumatoid Arthritis: improvement in signs/symptoms vs baseline (e.g., tender/swollen joint counts, CRP, patient global), or improvement on a disease activity scoring tool (e.g., DAS28 improvement ≥1.2 or ACR20 ≥20%).DAS28 improvement >=1.2 or ACR20 >=20%
CD_response: Crohn's Disease: improvement in signs/symptoms vs baseline (e.g., endoscopic activity, stools, abdominal pain, weight regain, hematocrit, biomarkers like fecal calprotectin or CRP, or Harvey-Bradshaw Index).clinical and/or biomarker improvement
PsA_response: Psoriatic Arthritis: improvement in tender/swollen joint counts, CRP, patient global, imaging changes, or disease activity scoring tool.clinical or imaging improvement
Covered when disease response is demonstrated as follows:
pJIA response criteria: Improvement in signs and symptoms compared to baseline such as number of tender and swollen joint counts, reduction in C-reactive protein, improvement in patient global assessment, and/or improvement on a disease activity scoring tool (e.g., JADAS or ACR‑Pedi 30 with at least 30% improvement from baseline in three of six variables).ACR-Pedi 30 or equivalent
Covered when disease response is demonstrated as follows:
nr-axSpA response criteria: Improvement in signs and symptoms compared to baseline such as total back pain, physical function, reduction of CRP, and/or improvement on a disease activity scoring tool (e.g., ≥1.1 improvement on ASDAS, ASDAS‑MI, ≥2 improvement on BASDAI, improvement in ASQoL, or ASAS40 response).ASDAS ≥1.1 or ASAS40
Plaque Psoriasis (PsO) — disease response and dose escalation conditions
Covered when disease response is demonstrated and dosing milestones met; dose escalation allowed on case-by-case basis when below criteria met:
PsO initial response and escalation prerequisites: Improvement in signs and symptoms compared to baseline (e.g., redness, thickness, scaliness, BSA ≤1%, PASI ≤3, PGA ≤1); AND shown initial response to therapy; AND received three loading doses at the specified dose/interval; AND received a minimum of one maintenance dose at the specified dose/interval; AND responded by treatment week 6 with subsequent loss of response to justify escalation.PASI ≤3 or PGA ≤1 or BSA ≤1%
Dose escalation limited to maximum dose/frequency specified in dosing section.
Dosing/Administration — loading and maintenance schedules
Dosing schedules by indication:
Typical adult loading/maintenance: Loading: 400 mg subcutaneously at weeks 0, 2, and 4; Maintenance: 200 mg subcutaneously every other week thereafter (or 400 mg every 4 weeks). Note: 400 mg doses are administered as two 200 mg injections.400 mg loading; 200 mg Q2W maintenance
PsA and pediatric dosing: PsA: Loading 400 mg at weeks 0, 2, and 4; then maintenance 200 mg every other week (or 400 mg every 4 weeks). Pediatric polyarticular dosing by weight bands: 10–<20 kg: loading 100 mg then maintenance 50 mg Q2W; 20–<40 kg: loading 200 mg then maintenance 100 mg Q2W; ≥40 kg: loading 400 mg then maintenance 200 mg Q2W. Note: no formulation for self-administration below 200 mg; doses <200 mg require administration by a health care professional using the vial kit.weight-based pediatric dosing as specified
Management of immune checkpoint inhibitor-related toxicity: Dose: 200 mg subcutaneously every other week (or 400 mg every 4 weeks) up to a single 400 mg dose as indicated.
Diagnosis-code based coverage
Covered when the member has one of the ICD-10 diagnosis codes listed in Appendix 1
Appendix 1 diagnosis match: Member's submitted diagnosis must be one of the ICD-10 codes listed in Appendix 1 of the policy.
Appendix contains extensive list of RA, juvenile arthritis, ankylosing spondylitis and related codes; see full appendix for code-specific entries
Patients must not have an active infection at the time of initiation and providers must confirm the member has not received live vaccines immediately prior to treatment and will not receive live vaccines during therapy. Initiation should be deferred until infections are resolved and vaccine timing is appropriate per the universal screening requirements.
Coverage is not allowed for members who are receiving concurrent treatment with another biologic therapy or a targeted synthetic therapy. Prior authorization requires confirmation the member is not on overlapping biologic/targeted synthetic agents.
When a phototherapy trial is part of the prior-therapy requirement for plaque psoriasis, members with listed contraindications to phototherapy (for example, xeroderma pigmentosum, certain photosensitive genodermatoses, pregnancy/lactation for PUVA, lupus erythematosus, prior photosensitivity disorders or history of skin cancer, immunosuppression post-transplant, severe liver/renal/cardiac disease for PUVA, young age <12 years for PUVA, or anatomic locations ineligible for phototherapy) are exempt from the phototherapy trial and will be reviewed on a case‑by‑case basis.
There is no Cimzia formulation that permits self‑administration for doses below 200 mg. Any ordered dose less than 200 mg requires administration by a health care professional using the vial kit in an appropriate clinical setting.
Medicare Part B covered diagnosis codes for Cimzia are listed as N/A in this policy. Where Medicare NCDs, LCDs, or LCAs exist, those CMS policies and contractor-specific guidance take precedence and may change coverage determinations for Medicare members.
Use of Cimzia without documented pre‑treatment screening and verification is not consistent with medical necessity. Providers must document HBV screening, completion of latent TB screening with ongoing monitoring, and up‑to‑date age‑appropriate vaccination status prior to initiation; absence of these verifications would not meet medical necessity.
Billing, Codes, and Authorization Durations
HCPCS unit dosing limitsHCPCS
400 billable units
Management of Immune Checkpoint Inhibitor-Related Toxicities — 1 dose; Plaque Psoriasis every other week; Loading doses for pJIA and other indications
Special-case noteManagement of Immune Checkpoint Inhibitor-Related Toxicities: prior authorization validity may NOT be renewed
Renewal prior authorization duration — inv-30: 365 days
Renewal prior authorization duration365 days (12 months)
Standard renewal frequency
Prior Authorization, Documentation, and Billing Guidance
Prior Authorization
Obtain prior authorization — validity and site-of-care
Prior authorization is required for Cimzia. Initial approvals are provided for 6 months (180 days); renewals may be authorized every 12 months (365 days). Site-of-care specialty infusion program requirements apply when relevant (refer to Moda Site of Care Policy).
Initial prior authorization validity: 180 days.
Renewal prior authorization validity: 365 days.
Site-of-care specialty infusion program requirements must be met when applicable.
Prior Authorization
Prior authorization required — document prior trials or continuation
Submit a prior authorization request demonstrating the member meets indication-specific criteria and that the member has had prior trial and inadequate response, contraindication, or intolerance to required alternative agents (requirements differ by indication and by Commercial vs Medicaid). Continuing treatment is an alternative pathway.
Provide documentation of prior therapy trials (3-month trials for most alternatives unless otherwise noted).
Drug Background and Context
Certolizumab pegol (Cimzia) is an anti‑TNF biologic indicated for multiple inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. The policy requires objective baseline assessment and prior‑therapy documentation, and specifies dosing schedules, administration, and prior authorization requirements to ensure appropriate and safe use.
Definitions, Response Criteria, and NQTLs
HCPCS billable units — maximum billable units per dose and over time
Per-dose maximumsPer dosing table: 400 billable units (common maximum per single dose for adult loading/maintenance where applicable)
pJIA maintenance200 billable units every other week for pJIA maintenance dosing
All-other-indications maintenance400 billable units every 4 weeks for most adult indications (alternative: 200 mg every other week)
ICI-related toxicityManagement of ICI-related toxicities: 400 billable units x 1 dose maximum
Contraindications to phototherapy — examples
Xeroderma pigmentosumListed as a contraindication to phototherapy (PUVA/UVB)
Policy Summary
PayerModa Health
PolicyCimzia (certolizumab pegol) (Subcutaneous) — Prior Authorization and Coverage Criteria
Policy CodePolicy M-0028
Change TypeNo material changes
Effective DateMar 3, 2026
Last ReviewMar 3, 2026
Next Review DateMar 3, 2026
Key ActionObtain prior authorization with documentation of baseline objective disease severity, required prior therapy trials or contraindications, and required pre-treatment screening (HBV and latent TB) before initiating Cimzia.
For Commercial members: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, tofacitinib, upadacitinib, or tocilizumab SC; OR member is continuing treatment.
3 months (where applicable)
Commercial step therapy
Medicaid step: For Medicaid members: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, or tocilizumab SC; OR member is continuing treatment.3 months (where applicable)
Medicaid step therapy
Commercial step therapy for CD
Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab or ustekinumab SC; OR member is continuing treatment.3 months
Medicaid step therapy for CD
Commercial step therapy for PsA
Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, secukinumab, or ustekinumab SC; OR member is continuing treatment.3 months
Medicaid step therapy for PsA
Medicaid step: Medicaid: inadequate response, contraindication, or intolerance to at least one of adalimumab, etanercept, or secukinumab; OR member is continuing treatment.3 months
Medicaid step therapy for AS
Dosing: Loading doses: 400 units subcutaneously at weeks 0, 2, and 4; maintenance: 200 units subcutaneously every other week.
pJIA dosing limits
AS_response: Ankylosing Spondylitis: improvement in back pain, function, morning stiffness, or scoring tools (e.g., ASDAS improvement ≥1.1 or BASDAI improvement ≥2).ASDAS >=1.1 or BASDAI >=2
pJIA_response: pJIA: improvement in signs/symptoms vs baseline (e.g., tender/swollen joints, CRP, patient global), or improvement on JADAS or ACR-Pedi 30 (≥30% improvement in 3 of 6 variables).ACR-Pedi 30 >=30%
nr-axSpA_response: nr-axSpA: improvement in back pain, function, CRP, or scoring tools (e.g., ASDAS improvement ≥1.1, ASDAS-MI, BASDAI improvement ≥2, or ASAS40).ASDAS >=1.1 or BASDAI >=2 or ASAS40
200 mg Q2W
Authorizations may be renewed every 12 months unless otherwise specified
ExceptionSee indication-specific rules (e.g., some indications may not be renewed)
Plaque Psoriasis severity thresholds — inv-31
Severity threshold — BSAInvolvement of at least 10% body surface area (BSA)
Severity threshold — PASIPsoriasis Area and Severity Index (PASI) score ≥10
Severity threshold — functional/psychosocial impactIncapacitation or serious emotional consequences due to plaque location or intractable pruritis
Minimum disease durationDocumented moderate to severe plaque psoriasis for at least 6 months
Prior therapy requirement summaryFailure or intolerance to topical agents (≥4 weeks), at least one non-biologic systemic agent (≥3 months), and phototherapy (≥3 months) unless already on biologic/targeted therapy or BSA >10%
Psoriasis dosing note — inv-32
Weight-based initiation guidanceMembers with body weight ≤90 kg should initiate at the lower dosing regimen: 200 mg every other week plus loading doses
Applies toPlaque psoriasis patients (note in dosing section for body weight ≤90 kg)
RationaleSpecified in the plaque psoriasis initial therapy criteria as dosing note for lower-weight patients
HCPCS billable units — inv-55
HCPCS unit definition (per policy dosing tables)Billable units referenced correspond to mg-equivalent dosing limits for indications (e.g., 200 and 400 billable units)
Common per-dose maximum400 billable units per dose (used for loading doses and some maintenance regimens)
pJIA maintenance unit200 billable units every other week for pJIA maintenance
All other indications maintenance400 billable units every 4 weeks (maintenance for most adult indications)
Immune checkpoint toxicity billingManagement of immune checkpoint inhibitor-related toxicities: 400 billable units x 1 dose
Indicate if the request is for continued treatment for a member already established on biologic/targeted synthetic therapy.
Note
Include dosing and response documentation; bill correctly
For prior authorization, document indication-specific baseline and response measures and confirm adherence to required loading and maintenance dosing (e.g., receipt of three loading doses when applicable). If provider-administered, billing may use HCPCS J0717 per policy.
Document objective baseline measures and evidence of response on renewal (see disease-specific tools).
Document receipt of loading doses and maintenance dosing as specified (e.g., 400 mg at weeks 0,2,4 then maintenance 200 mg Q2W or 400 mg Q4W).
If drug is administered by provider, bill using J0717 (injection, certolizumab pegol, 1 mg) where appropriate.
Note
PA applied after NQTL review (indication, safety, cost)
Prior authorization is applied after consideration of NQTL factors; the NQTL checklist shows indication, safety/efficacy, and drug cost were reasons to consider prior authorization for this drug.
NQTL factors considered: indication (Yes), safety and efficacy (Yes), cost (Yes), potential for misuse/abuse (No).
Documentation Required
Submit Appendix 1 ICD-10 code; follow Medicare guidance where applicable
When requesting coverage or submitting claims, include an appropriate ICD-10 diagnosis code from Appendix 1. For Medicare members, applicable NCD/LCD/LCA or Medicare contractor requirements may supersede — reference CMS/Medicare guidance where relevant.
Use an Appendix 1 ICD-10 code that matches the member's diagnosis on prior authorization and claim submissions.
Check Medicare NCD/LCD/LCA guidance for Part B where applicable; Medicare Part B covered diagnosis codes are listed as N/A in this policy but contractor rules may apply.
Step Therapy
Document required prior agent trials per indication
For each indication, provide documentation that required prior agent trials were completed and that the member had inadequate response, contraindication, or intolerance to those agents (specific lists differ by indication and by Commercial vs Medicaid).
Commercial and Medicaid required alternative agent lists differ by indication — include which agent(s) were trialed and trial duration (commonly 3 months).
If member is already established on biologic/targeted synthetic therapy, document that status as an alternative to step therapy.
Step Therapy
Confirm step-therapy trials and duration (usually 3 months)
Ensure documentation shows the member tried and had inadequate response, contraindication, or intolerance to specified alternative agents for the required trial period (typically a 3-month trial) before approving Cimzia, unless the member is already established on therapy.
Typical required trial duration for alternatives is 3 months unless otherwise specified.
Document specific alternative agent(s) tried and clinical reason for failure/intolerance/contraindication.
Documentation Required
Psoriasis dose escalation requires documented initial response and dosing milestones
For plaque psoriasis, dose escalation is permitted only after the patient has shown initial response, received the three specified loading doses and at least one maintenance dose, and demonstrated response by treatment week 6 with subsequent loss of response to justify escalation.
Required: documentation of initial response, receipt of loading doses (400 mg at weeks 0, 2, 4) and at least one maintenance dose before escalation.
Dose escalation limited to maximum dose/frequency specified in the dosing section and considered case-by-case.
Note
Step therapy sequences: not fully specified here — see indication sections
This section does not list a step-by-step sequence for step therapy; the NQTL checklist explains factors considered for PA design but specific step therapy sequences are provided within indication-specific criteria elsewhere in the policy.
Review indication-specific sections for the precise alternative agents required per member type (Commercial vs Medicaid).
Documentation Required
Document baseline disease severity with objective measures
Document baseline disease severity using an objective tool and evidence of moderate-to-severe (or active) disease for the indicated condition when submitting a PA request.
Use disease-specific objective measures (e.g., DAS28, JADAS, PASI, CRP, MRI findings) as described in the indication-specific criteria.
Include documented assessment confirming moderate-to-severe or active disease.
Provide pre-treatment screening documentation: hepatitis B virus (HBV) screening, latent tuberculosis (TB) screening with plan for ongoing monitoring, verification of up-to-date vaccinations, and confirmation the member is not receiving another biologic or targeted synthetic therapy.
HBV screening must be completed prior to initiating treatment.
Latent TB screening must be completed prior to initiating treatment with ongoing monitoring during therapy.
Confirm member has not recently received live vaccines and is up to date with age-appropriate vaccinations.
Documentation Required
Submit baseline and objective response data at renewal
For renewals, provide objective documentation of disease response compared to baseline using indication-specific tools (e.g., DAS28 or ACR20 for RA; Harvey‑Bradshaw Index or CRP for Crohn's; JADAS or ACR‑Pedi for pJIA; ASDAS/BASDAI or ASAS40 for nr-axSpA; PASI/PGA/BSA for PsO).
Include the baseline objective measure and the measure at renewal to demonstrate improvement.
Renewal requires meeting the renewal criteria and absence of unacceptable toxicity.
Documentation Required
For PsO escalation, document loading doses, initial response, and maintenance dosing
When considering psoriasis dose escalation, document initial clinical response and confirm the member received the three loading doses and at least one maintenance dose at the specified intervals prior to escalation.
Document timing and dosing of the three loading doses (400 mg at weeks 0, 2, 4) and at least one maintenance dose.
Show initial response and subsequent loss of response by treatment week 6 to support escalation.
Documentation Required
Document the required diagnosis using Appendix 1 ICD-10 codes
Include the member's ICD-10 diagnosis code from Appendix 1 on the prior authorization and claim submissions; Appendix 1 contains the covered diagnosis codes (e.g., K50.x, L40.x, M05.x series).
Use an Appendix 1 code that matches the clinical diagnosis exactly when requesting coverage.
Require submission of Appendix 1 ICD-10 code on PA/claim
When requesting coverage, submit the member's ICD-10 diagnosis code from Appendix 1 with the PA request; the appendix contains the covered diagnosis codes for rheumatoid and juvenile arthritis and related spondyloarthritis and dermatologic conditions.
Ensure the submitted diagnosis code is listed in Appendix 1 to avoid coverage denial.
If the diagnosis is not listed in Appendix 1, coverage may be denied (see diagnosis-code based denial risk).
Denial Risk
Clinical exclusions that may trigger denial (infection, vaccines, concurrent biologics)
Do not initiate or continue Cimzia in the presence of active infection, recent live vaccines, lack of required TB screening/monitoring, or if the member is receiving another biologic/targeted synthetic therapy — these clinical exclusions can trigger denial.
Active infection or clinically important localized infections are exclusions to initiation.
Members must not receive live vaccines immediately prior to or during therapy.
Concurrent treatment with another biologic or targeted synthetic therapy is not allowed.
Denial Risk
Renewal denials: expired authorization or unacceptable toxicity
Renewal may be denied if the authorization duration has been exceeded or if there is unacceptable toxicity from the drug — examples include severe hypersensitivity, serious infection, heart failure, lupus‑like syndrome, demyelinating disease, cytopenias, malignancy, or hepatitis B reactivation.
Verify authorization duration and that renewal criteria are met before submitting a renewal.
Document absence of unacceptable drug-related toxicity to support renewal.
Billing Rule
Avoid billing misuse of J0717 for self-administered doses
Do not bill J0717 when the product is self-administered; J0717 is for physician‑supervised administration and inappropriate use of this code for self‑administered doses may trigger claim denial.
Use J0717 only when the drug is administered under direct physician supervision per Medicare guidance; it is not for self-administered product.
Note
NQTL findings that supported prior authorization
Prior authorization and utilization management were designed after reviewing NQTL factors; indication, safety/efficacy, and cost supported consideration of PA for Cimzia and may trigger PA requirements.
NQTL checklist: indication (Yes), safety/efficacy (Yes), cost (Yes) — these drove PA design.
Utilization management methods are applied comparably across MH/SUD and M/S drugs per the appendix.
Denial Risk
Diagnosis-code based denial risk — use Appendix 1 codes
Use of Cimzia for a diagnosis not listed in Appendix 1 may lead to coverage denial if no applicable Appendix 1 ICD-10 code is submitted with the request or claim.
Confirm the member's diagnosis code is included in Appendix 1; otherwise, coverage may be denied.
Appendix 1 contains extensive lists of covered codes for RA, pJIA, nr-axSpA, PsO, and Crohn's disease.
Other photosensitive genodermatosesExamples include trichothiodystrophy, Cockayne syndrome, Bloom syndrome, Rothmund-Thomson syndrome (UVB only)
Pregnancy or lactationPregnancy or lactation is a contraindication to PUVA phototherapy
Lupus erythematosusListed as a contraindication to phototherapy
History of photosensitivity or skin cancerHistory of photosensitivity diseases, melanoma, non-melanoma skin cancer, or extensive solar damage may contraindicate phototherapy
pJIA response — indicators of improvement
Joint counts improvementImprovement in number of tender and swollen joint counts compared to baseline
CRP reductionReduction in C‑reactive protein (CRP) from baseline
Disease activity scoresImprovement on a disease activity tool such as JADAS or ACR‑Pedi 30 (≥30% improvement in 3 of 6 variables)
Patient global assessmentImprovement in patient global assessment compared to baseline
nr-axSpA response — improvement measures
Back pain and functionImprovement in total back pain and physical function compared to baseline
CRP reductionReduction in C‑reactive protein (CRP)
ASDAS/BASDAI/ASAS thresholdsStandardized improvements such as ≥1.1 improvement on ASDAS, ASDAS‑MI (≥2.0 for major improvement), ≥2 improvement on BASDAI, or ASAS40 response
Quality of lifeImprovement in ASQoL score from baseline
PsO response — improvement measures and initial response requirements
BSA/PASI/PGA targetsResponse may be demonstrated by BSA ≤1%, PASI ≤3, or PGA ≤1 compared to baseline
Initial response prerequisiteDose escalation is permitted only after shown initial response and receipt of three loading doses plus at least one maintenance dose
Timing for escalationResponded by treatment week 6 with subsequent loss of response may justify escalation
Non-Quantitative Treatment Limitations (NQTL)
DefinitionNQTLs are methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan
Examples of NQTLsUtilization review and prior authorization are examples of NQTLs used to manage benefit extent/duration
Factors consideredPolicy NQTL checklist considered indication, safety/efficacy, potential misuse, and drug cost when designing PA
Appendix 1 — Covered Diagnosis Codes (definition)
DefinitionAppendix 1 is the policy list of covered ICD‑10 diagnosis codes for conditions where Cimzia may be medically necessary
Use in submissionsProviders should submit an Appendix 1 ICD‑10 code when requesting coverage
ScopeAppendix contains extensive RA, juvenile arthritis, ankylosing spondylitis, psoriasis and related codes; see full appendix for details
Appendix 2 — CMS/Medicare guidance
Medicare guidance sourceMedicare Part B coverage is governed by the Medicare Benefit Policy Manual (Pub. 100‑02), Chapter 15, §50, and applicable NCDs/LCDs/LCAs
Local/jurisdictional applicabilityNCDs, LCDs, and LCAs may exist and must be followed where applicable; links provided to CMS coverage database
Medicare Part B codes notePolicy notes Medicare Part B covered diagnosis codes as N/A in this document; existing NCD/LCD/LCA requirements may supersede policy provisions